Shanghai Junshi Biosciences Stock Net Income
| 688180 Stock | 29.97 0.13 0.43% |
Shanghai Junshi Biosciences fundamentals help investors to digest information that contributes to Shanghai Junshi's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Junshi's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Junshi stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -2.5 B | -2.4 B | |
| Net Loss | -2.2 B | -2.1 B | |
| Net Loss | -2.2 B | -2.1 B |
Shanghai | Net Income |
Shanghai Junshi Biosciences Company Net Income Analysis
Shanghai Junshi's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Shanghai Junshi Net Income | (2.25 B) |
Most of Shanghai Junshi's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Junshi Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Shanghai Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Shanghai Junshi Biosciences reported net income of (2.25 Billion). This is 758.52% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all China stocks is significantly higher than that of the company.
Shanghai Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Junshi's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Junshi could also be used in its relative valuation, which is a method of valuing Shanghai Junshi by comparing valuation metrics of similar companies.Shanghai Junshi is currently under evaluation in net income category among its peers.
Shanghai Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 24.9 B | ||||
| Shares Outstanding | 765.58 M | ||||
| Shares Owned By Insiders | 29.59 % | ||||
| Shares Owned By Institutions | 25.12 % | ||||
| Price To Book | 4.56 X | ||||
| Price To Sales | 14.29 X | ||||
| Revenue | 1.5 B | ||||
| Gross Profit | 1.45 B | ||||
| EBITDA | (1.61 B) | ||||
| Net Income | (2.25 B) | ||||
| Total Debt | 539.39 M | ||||
| Book Value Per Share | 28.15 X | ||||
| Cash Flow From Operations | (2.01 B) | ||||
| Earnings Per Share | (1.97) X | ||||
| Target Price | 39.0 | ||||
| Number Of Employees | 2.57 K | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 25.53 B | ||||
| Total Asset | 11.36 B | ||||
| Retained Earnings | (9.04 B) | ||||
| Working Capital | 3.07 B | ||||
| Net Asset | 11.36 B |
About Shanghai Junshi Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Junshi Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Junshi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Junshi Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Junshi financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Junshi security.